Avita Therapeutics Inc logo

RCEL - Avita Therapeutics Inc Share Price

$23.43 0.4  1.6%

Last Trade - 8:06pm

Large Cap
Market Cap £33.35bn
Enterprise Value £33.29bn
Revenue £8.90m
Position in Universe 224th / 6368
Unlock RCEL Revenue
Relative Strength (%)
1m -26.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
2.68 0.99 1.11 1.30 1.27 8.16 27.8 38.2 +24.9%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2019, Avita Therapeutics Inc revenues increased from A$1.9M to A$10M. Net loss increased 35% to A$21M. Revenues reflect Sale of goods increase from A$1.8M to A$9.7M, Other income increase from A$104K to A$297K. Higher net loss reflects Share based payment expense increase from A$1M to A$5.3M (expense), Sales and marketing expenses increase of 49% to A$10.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RCEL Revenue Unlock RCEL Revenue

Net Income

RCEL Net Income Unlock RCEL Revenue

Normalised EPS

RCEL Normalised EPS Unlock RCEL Revenue

PE Ratio Range

RCEL PE Ratio Range Unlock RCEL Revenue

Dividend Yield Range

RCEL Dividend Yield Range Unlock RCEL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RCEL EPS Forecasts Unlock RCEL Revenue
Profile Summary

AVITA Therapeutics, Inc., formerly Avita Medical Limited, is a regenerative medicine company with a technology platform to address medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. Its technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. Its product, the RECELL System for the treatment of acute thermal burn injuries in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a way to treat severe burns that significantly reduces the amount of donor skin required. It is designed to be used at the point of care alone or in combination with split-thickness skin autografts depending on the depth of the burn injury.

Last Annual June 30th, 2019
Last Interim December 31st, 2019
No. of Shareholders: 6,327
No. of Employees: 87
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 93,564,979
Free Float (0.0%)
Eligible for
RCEL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RCEL
Upcoming Events for RCEL
Frequently Asked Questions for Avita Therapeutics Inc
What is the Avita Therapeutics Inc share price?

As of 8:06pm, shares in Avita Therapeutics Inc are trading at $23.43, giving the company a market capitalisation of £33.35bn. This share price information is delayed by 15 minutes.

How has the Avita Therapeutics Inc share price performed this year?

Shares in Avita Therapeutics Inc are currently trading at $23.43 and the price has moved by -9.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Avita Therapeutics Inc price has moved by -21.09% over the past year.

What are the analyst and broker recommendations for Avita Therapeutics Inc?

There are no analysts currently covering Avita Therapeutics Inc.

When will Avita Therapeutics Inc next release its financial results?

Avita Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Avita Therapeutics Inc dividend yield?

Avita Therapeutics Inc does not currently pay a dividend.

Does Avita Therapeutics Inc pay a dividend?

Avita Therapeutics Inc does not currently pay a dividend.

When does Avita Therapeutics Inc next pay dividends?

Avita Therapeutics Inc does not currently pay a dividend.

How do I buy Avita Therapeutics Inc shares?

To buy shares in Avita Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Avita Therapeutics Inc?

Shares in Avita Therapeutics Inc are currently trading at $23.43, giving the company a market capitalisation of £33.35bn.

Where are Avita Therapeutics Inc shares listed? Where are Avita Therapeutics Inc shares listed?

Here are the trading details for Avita Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: RCEL
What kind of share is Avita Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Avita Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Avita Therapeutics Inc share price forecast 2020?

Shares in Avita Therapeutics Inc are currently priced at $23.43. At that level they are trading at 2.88% discount to the analyst consensus target price of 0.00.

Analysts covering Avita Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.5922846 for the next financial year.

How can I tell whether the Avita Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avita Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -51.17%. At the current price of $23.43, shares in Avita Therapeutics Inc are trading at -36.31% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Avita Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Avita Therapeutics Inc.

Who are the key directors of Avita Therapeutics Inc?

Avita Therapeutics Inc's management team is headed by:

William Marshall - VOP
Andrew Quick - CTO
Michael Perry - CEO
Tim Rooney - CAD
Lou Panaccio - CHM
Jeremy Cook - NED
Louis Drapeau - NED
Damien McDonald - NED
Suzanne Crowe - NED
Ross Saunders - VPR
Troy Barring - COO
Dale Sander - CFO
Mark Licciardo - SEC
Donna Shiroma - GCN
Terry Bromley - VOP
Debbie Garner - VPR
Katie Bush - VPR
Tamara Barr - SEC
Erin Liberto - OTH
David McIntyre - CFO
Who are the major shareholders of Avita Therapeutics Inc?

Here are the top five shareholders of Avita Therapeutics Inc based on the size of their shareholding:

Blackcrane Capital, LLC Investment Advisor
Percentage owned: 4.88% (1.03m shares)
SEI Investments Management Corporation Investment Advisor
Percentage owned: 2.69% (570k shares)
Acadian Asset Management LLC Investment Advisor/Hedge Fund
Percentage owned: 2.37% (502k shares)
SEI Institutional International - Intl. Equity Mutual Fund
Percentage owned: 2.37% (502k shares)
Perry (Michael S) Individual Investor
Percentage owned: 1.64% (348k shares)
Similar to RCEL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.